

Gastric Cancer Research

International Cancer Advocacy Network

Esraa H., Armin M., Fiza N.

Cancer of the Stomach - Outline

1. Etiology
 - a. [Acquired Factors](#)
 - i. Coal Workers (Pages 2-11)
 - ii. Helicobacter pylori (12-21)
 - iii. Epstein-Bar Virus (22-35)
 - iv. Low Intake of Vitamin A and C (36-44)
 - v. Smoking (45-54)
 - b. [Genetic](#)
 - i. Type A Blood (Pages 2-13)
 - ii. Pernicious anemia (14-24)
 - iii. E-cadherin gene (25-39)
 - c. Pathology
 - i. [Boormann Classification by Type](#)
 1. Type 1- Polypoid or fungating cancers (Pages 2-7)
 2. Type 2- Ulcerating Lesions (8-12)
 3. Type 3- Ulcerating Lesions surrounding gastric wall (13-17)
 4. Type IV- Diffusely Infiltrating Tumors (18-23)
 5. Type V- Unclassifiable (24-30)
 - ii. [Boormann Classification by Grade \(Modified\)](#)
 1. Recent publication relating to the advancement of gastric cancer pathology (Pages: 2-9)
 2. Established gastric cancer pathology research – including a focus on Boormann type IV gastric cancer (10-26)
 - d. [Patterns of Diffusion](#)
 - i. Lymphatic metastases (Pages 2-20)
 - ii. Peritoneal metastasis (21-36)
 - iii. Distan metastasis (37-52)
2. Clinical Presentation
 - a. [American Joint Committee on Cancer/International Union Against Cancer](#)
 - i. T1- Submucosa (Pages 2-10)
 - ii. T2- Submucosa (11-22)
 - iii. T3- Mucularis propria (23-28)
 - iv. T4- Contiguous structure (29-31)
 - b. [Japanese Classification System](#)
 - i. Type OI- Protruded Type (Pages 2-12)
 - ii. Type OIIa- Superficial elevated (13-25)
 - iii. Type OIIb- Flat type (26-36)
 - iv. Type OIIc- Superficial depressed (37-49)
 - v. Type OIIL- Excavated type (50-60)
3. Treatment
 - a. [Stage 1](#)

- i. Endoscopic mucosal resection (Pages 2-24)
 - ii. Limited surgical resection (25-49)
 - iii. Gastrectomy (50-79)
- b. [Stage 2/3](#)
 - i. Surgical resection (partial or total) (Pages 2-28)
 - ii. Surgical resection and surrounding lymphadenectomy, or all previous along with Pancreatectomy or all previous with Splenectomy and resection or all previous along with chemotherapy (29-53)
 - iii. Resection and intra peritoneal chemotherapy and or immunchemotherapy (54-79)
- c. Adjuvant Therapy
 - i. Arabinosylcytosine ++Part 1++ (Pages 2-23)
 - ii. Chloroethylcyclohexyltriazolopyrimidine (24-46)
 - iii. Cyclophosphamide (47-69)
 - iv. Methotrexate (70-96)
 - v. Fluorouracil (97-121)
 - vi. Vincristine ++Part 2++ (Pages 2-26)
 - vii. Doxorubicin (27-52)
 - viii. Radiation therapy (53-76)
 - ix. Taxane (77-99)